Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report

Dai Koguchi; Ken-Ichi Tabata; Hideyasu Tsumura; Kohei Mori; Hideshige Koh; Masatsugu Iwamura

doi:10.1016/j.eucr.2021.101712

Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report

Urol Case Rep. 2021 May 17:38:101712. doi: 10.1016/j.eucr.2021.101712. eCollection 2021 Sep.

Authors

Dai Koguchi^{1

2}, Ken-Ichi Tabata², Hideyasu Tsumura², Kohei Mori^{1

2}, Hideshige Koh^{1

2}, Masatsugu Iwamura²

Affiliations

¹ Department of Urology, Yokosuka General Hospital Uwamachi, Kanagawa, Japan.
² Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan.

Abstract

Poly (ADP-ribose) polymerase inhibitors exhibit strong activity for treating the DNA damage repair defect in patients with prostate carcinoma (PCa). Although conventional DNA-damaging agents can theoretically lead to synthetic antitumoral effects, no report has clearly mentioned the clinical use of cisplatin for treating PCa patients with the breast cancer gene (BRCA)2 mutation. We administered 80 mg/m² cisplatin triweekly to a patient with metastatic castration-resistant PCa (mCRPC) with the BRCA2 mutation, and after ten cycles, the prostate-specific antigen was dramatically decreased. We suggest that BRCA2 mutations may indicate the use of cisplatin for treating patients with mCRPC.

Keywords: BRCA2 mutation; Cisplatin; DNA damage Repair defect; Prostate cancer.

Publication types

Case Reports